Tharimmune (THAR) said Monday it plans to initiate a phase 2 study that will evaluate TH104 in reducing itch in patients with primary biliary cholangitis, a rare, chronic liver disease.
The clinical trial, expected to begin in 2025, follows results from a phase 1 study and recent regulatory feedback from the European Medicines Agency and the US Food and Drug Administration, the biotechnology company said.
Preliminary results from the trial, which has a planned enrollment of 40 patients, are expected in late 2025, the company said.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments